14040 nagrań 880 konferencji 3731 wykładowców Zrealizuj voucher

Uzyskaj dostęp do najwyższej jakości wiedzy medycznej. Zarejestruj się »

prof. dr hab. n. med. Maciej Krzakowski

Primary results from TAIL, a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

Primary results from TAIL, a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

ESMO highlights 2019 - Roche - Płuco - 29.09.2019 Barcelona.

Primary results from TAIL, a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC Mok.

 

Primary results from TAIL, a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer